MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype

Journal of Surgical Research

Volumn 158, Issue 1, 2010, Pages 15-19

  Chen, Jui yu ^a,b   Cook, Mackenzie R ^a   Pinchot, Scott N ^a   Kunnimalaiyaan, Muthusamy ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

apoptosis; ASCL1; carcinoid; glycogen synthase kinase 3 ; MG 132; proteasome inhibitor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CHROMOGRANIN A; GLYCOGEN SYNTHASE KINASE 3BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TRANSCRIPTION FACTOR MASH1;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GASTROINTESTINAL CARCINOID CELL; HUMAN; HUMAN CELL; LUNG CARCINOID CELL; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOID TUMOR; CELL PROLIFERATION; CHROMOGRANIN A; CYSTEINE PROTEINASE INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUPEPTINS; NEUROSECRETORY SYSTEMS; PHENOTYPE; PHOSPHORYLATION; TUMOR CELLS, CULTURED;

EID: 71649102450     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2009.05.032     Document Type: Article

References (27)

1. Pinchot S.N., Holen K., Sippel R.S., et al. Carcinoid tumors. Oncologist 13 (2008) 1255
2. Chen H., Hardacre J., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 187 (1998) 88 discussion 92
3. Lal A., and Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 18 (2006) 9
4. Shah S., Potter M., and Callery M. Ubiquitin proteasome pathway: Implications and advances in cancer therapy. Surg Oncol 10 (2001) 43
5. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14 (2002) 628
6. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4 (2004) 349
7. Richardson P.G., Mitsiades C., Hideshima T., et al. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57 (2006) 33
8. Wu W.K., Sung J.J., Wu Y.C., et al. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol 154 (2008) 632
9. Yan X.B., Yang D.S., Gao X., et al. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int 31 (2007) 1136
10. Codony-Servat J., Tapia M.A., Bosch M., et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5 (2006) 665
11. Kunnimalaiyaan M., Vaccaro A.M., Ndiaye M.A., et al. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 6 (2007) 1151
12. Hardt S.E., and Sadoshima J. Glycogen synthase kinase-3beta: A novel regulator of cardiac hypertrophy and development. Circ Res 90 (2002) 1055
13. Wang Q., Wang X., Hernandez A., et al. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 277 (2002) 36602
14. Kunnimalaiyaan M., Ndiaye M., and Chen H. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery 142 (2007) 959 discussion 959
15. Van Gompel J.J., Kunnimalaiyaan M., Holen K., et al. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 4 (2005) 910
16. Sippel R.S., Carpenter J.E., Kunnimalaiyaan M., et al. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 285 (2003) G245
17. Kunnimalaiyaan M., Traeger K., and Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 289 (2005) G636
18. Wang ZB, Liu YQ, Cui YF. Pathways to caspase activation. Cell Biol Int 2205;29:489.
19. Liao X., Thrasher J.B., Holzbeierlein J., et al. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145 (2004) 2941
20. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., et al. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65 (2005) 2076
21. Shakoori A., Ougolkov A., Yu Z.W., et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334 (2005) 1365
22. Kappes A., Vaccaro A., Kunnimalaiyaan M., et al. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res 133 (2006) 42
23. Kappes A., Vaccaro A., Kunnimalaiyaan M., et al. Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. Surgery 141 (2007) 161 discussion 165
24. Drexler H.C. The role of p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2 (2003) 438
25. Almond J.B., and Cohen G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16 (2002) 433
26. Holecek M., Muthny T., Kovarik M., et al. Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat. Biochem Biophys Res Commun 345 (2006) 38
27. Inoue S., Nakase H., Matsuura M., et al. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 156 (2009) 172